BCL2 and prostate carcinoma: In addition, cationic liposome LIC-101 and B717, a sequence-specific synthetic Bcl-2-siRNA was mixed to form B717/LIC-101 for exploring tumor inhibitory effect in a prostate cancer mouse model, developed by given 5 × 106 of PC-3 cells (prostate cancer cell) subcutaneously into 5 weeks old male Balb/C mice.